Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
60.38 73.61 113.10 111.26

+8 more quarters

P/S ratio
9.07 6.75 7.54 7.11
P/FCF ratio
41.86 30.30 41.09 38.60
P/Operating CF
115.48 94.27 111.21 313.52
P/B ratio
5.23 3.92 4.56 4.40
EV/Sales
9.03 6.75 7.62 7.25
EV/EBITDA
31.40 32.16 41.98 40.81
EV/FCF
41.66 30.31 41.54 39.35
Current Ratio
4.55 4.49 4.54 4.22
Net Debt/EBITDA
(0.66) (0.10) 1.10 2.15
Debt/Equity
0.09 0.10 0.13 0.15
Earnings Yield
1.66% 1.36% 0.88% 0.90%
Free Cash Flow Yield
2.39% 3.30% 2.43% 2.59%
Free Cash Flow per Share
0.56 0.50 0.49 0.14
Book value per Share
13.52 13.34 12.90 12.64
Free Cash Flow
86.94 77.58 76.49 22.22
EV/EBIT
43.54 53.15 79.21 80.20
Other line items

Show all line items

Columns are period end dates